Literature DB >> 2916326

Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2).

M Ohuchi1, M Orlich, R Ohuchi, B E Simpson, W Garten, H D Klenk, R Rott.   

Abstract

Six variants that form plaques in chick embryo cells in the absence of trypsin have been isolated from the apathogenic avian influenza virus A/chick/Pennsylvania/1/83 (H5N2). Unlike the wild-type, the plaque variants contain a hemagglutinin that is cleaved in chick embryo cells and MDCK cells. The variants differ also from the wild-type in their pathogenicity for chickens. Nucleotide sequence and oligosaccharide analysis of the hemagglutinin have revealed that, unlike natural isolates with increased pathogenicity (Y. Kawaoka et al., 1984, Virology 139, 303-316; Y. Kawaoka and R. G. Webster, 1985, Virology 146, 130-137), the variants obtained in vitro have retained an oligosaccharide at asparagine 11 that is believed to interfere with the cleavage site of the wild-type. However, all variants showed mutations in the hemagglutinin resulting in an increased number of basic groups at the cleavage site. These observations demonstrate that masking of the cleavage site by an oligosaccharide is overcome by an enhancement of the basic charge at the cleavage site.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916326     DOI: 10.1016/0042-6822(89)90267-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  51 in total

1.  Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety.

Authors:  M Ohuchi; R Ohuchi; A Feldmann; H D Klenk
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Generation of seal influenza virus variants pathogenic for chickens, because of hemagglutinin cleavage site changes.

Authors:  S Q Li; M Orlich; R Rott
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

3.  Cleavage of influenza a virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases.

Authors:  Oleg P Zhirnov; Mine R Ikizler; Peter F Wright
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

4.  H5N2 avian influenza outbreak in Texas in 2004: the first highly pathogenic strain in the United States in 20 years?

Authors:  Chang-Won Lee; David E Swayne; Jose A Linares; Dennis A Senne; David L Suarez
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Characterization of a temperature-sensitive influenza B virus mutant defective in neuraminidase.

Authors:  S Shibata; F Yamamoto-Goshima; K Maeno; T Hanaichi; Y Fujita; K Nakajima; M Imai; T Komatsu; S Sugiura
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin.

Authors:  P C Roberts; W Garten; H D Klenk
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  Structural features influencing hemagglutinin cleavability in a human influenza A virus.

Authors:  Y Kawaoka
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  A Unique Multibasic Proteolytic Cleavage Site and Three Mutations in the HA2 Domain Confer High Virulence of H7N1 Avian Influenza Virus in Chickens.

Authors:  El-Sayed M Abdelwhab; Jutta Veits; Kerstin Tauscher; Mario Ziller; Jens P Teifke; Jürgen Stech; Thomas C Mettenleiter
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

9.  Pathogenicity and phylogenetic evaluation of the variant Newcastle disease viruses termed "pigeon PMV-1 viruses" based on the nucleotide sequence of the fusion protein gene.

Authors:  M S Collins; I Strong; D J Alexander
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

10.  Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport.

Authors:  K Takeuchi; R A Lamb
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.